## N2 Referral form for Primary Samples being sent to NMRS-S

. .

discussed with.

## NB. Please include as much clinical information as possible to help minimise delays in testing and increase efficiency of our service.

1. Only use this form for submitting primary specimens for microscopy and culture, and/or PCR testing. Ensure you are using the most up- to-date version.	N2 UK Health Security Agency Agency KHSA Colindale DX South (MRS-South) NMRS-South (MRS-South)	2. Our address, including DX number. Mark all packages clearly for CL3/NMRS.
4. Clearly state your laboratory	Place who clawly in dark ink SENDER'S INFORMATION	3. Useful contact details for both lab and clinical enquiries.
sender details as this is where reports will be sent to. It is also helpful for clinicians to know this for when patients have been transferred between hospitals.	Name and address  Report to be sent FAO  Direct Phone number  Ext  E-mail  Purchase order number  Purchase order number	5. Include a name and contact details of a clinician so our clinicians have a point of contact when discussing results and treatment options.
6. Include all patient details listed here and ensure the sample has at least 3 matching patient identifiers between the request form and sample.	Referred by     Phone     Date       PATIENT/SOURCE INFORMATION       NHS number       Sumarie       Forename         Forename	7. Include patient's postcode and HPT if available as it aids in contact tracing.
8. Include your lab number for the sample. This is especially useful in helping us identify if there are multiple isolates from the same	Patient's HPT  Hospital number  Cinical / Patient's consultant  Inpatient Outpatient  SAMPLE INFORMATION  Vou reference  Date of collection  Time	10. Include the date the original sample was collected as this will affect how often we test the sample.
<ul> <li>patient.</li> <li>9. Tick the relevant specimen type. If not listed, tick 'other' and specify the exact specimen type, don't be vague. For example, if a tissue or a fluid, state where from. This will affect how we treat the sample what what work we do on it.</li> <li>13. Tick which test is required.</li> </ul>	Total reference.       Date sent to UKHSA         Specimen type *       Pleural Fluid         Incortical event data pation only       Pleural Fluid         Binonchaolevelar Lavage (BAL)       Splum         Blood       Tissue / Biopsy         Prease specify       "Note: A <u>minimum</u> of 0.5ml Whole CSF (e.g., not supernatant) is neight a decide of the other fluids require a <u>minimum</u> volume of fml.         Prease specify       TeSTS REOUESTED         MTBC RT-PCR & Rifampkin Resistance       Microscopy & Culture	11. Tick 'yes' in this box ONLY if there are suspicions that the patient is infected with a Hazard Group 4 pathogen or with CJD/ other prion disease. If so, this will not be opened or processed by NMRS-S until confirmation that these infection(s) have been ruled out. If only Hazard Group 2 or 3 pathogens suspected, tick 'no'.
Please note, primary specimens submitted for 'MTBC RT-PCR & rifampicin resistance' will be tested for the presence of <i>Mycobacterium tuberculosis</i> complex and mutations conferring resistance to rifampicin. Primary	MTBC RT-PCR for Extensive Drug Resistance (XDR). Please contact NMRS-South clinician <u>before</u> sending sample.      SENDER'S LABORATORY RESULTS      Microscopy &      Microscopy &      Inegative   Not Done   Positive Zehi-Neelsen   Positive Auramine-phenol Beading/ Cording Yes   No      seen?      TB detected by   TB PCR   TB CARD/ MPT64   Unknown Resistance      detected     Reason for test   Suspected TB Multi-Drug Resistant   Poor clinical progress   Detection of MTBC	14. If you have performed any preliminary tests in house, include the results in this section. Additional information here will help ensure the most effective testing.
specimens submitted for 'MTBC RT-PCR for extensive drug resistance' will be tested for the presence of <i>Mycobacterium</i>	CLINICAL/EPIDE/MIQL/OGICAL INFORMATION           Immunosuppressed?         Yes         No         Don't know         Other clinical details           HIV Positive?         Yes         No         Don't know         Other clinical details           On treatment?         Yes         No         Don't know         Other clinical details	15. Please tick to indicate which clinical details apply to the patient.
tuberculosis complex and mutations conferring resistance to isoniazid, fluoroquinolones, second line injectables, and ethionamide. However, this will ONLY be performed for specimens where rifampicin resistance has already been detected (provide	Of it requests are subject to UMHA standard terms and conditions.	16. Include any additional detail, such as clinical information that will aid our clinicians, previous results, if it is a repeat sample or if you have spoken to one of our clinicians regarding the request in these sections.
details on the form) or where it has been discussed with, and approved by, NMRS-S clinicians. Please state who this was		